4.7 Article

Using diffusion tensor imaging to detect cortical changes in fronto-temporal dementia subtypes

期刊

SCIENTIFIC REPORTS
卷 10, 期 1, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-020-68118-8

关键词

-

资金

  1. Frontotemporal Lobar Degeneration Neuroimaging Initiative (National Institutes of Health) [R01 AG032306]
  2. Alzheimer's Research UK (Network Pilot Award)
  3. Alzheimer's Research UK (Pilot Project Grant) [ARUK-PPG2017A-19]
  4. Wellcome Trust [203139/Z/16/Z]
  5. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)

向作者/读者索取更多资源

Fronto-temporal dementia (FTD) is a common type of presenile dementia, characterized by a heterogeneous clinical presentation that includes three main subtypes: behavioural-variant FTD, non-fluent/agrammatic variant primary progressive aphasia and semantic variant PPA. To better understand the FTD subtypes and develop more specific treatments, correct diagnosis is essential. This study aimed to test the discrimination power of a novel set of cortical Diffusion Tensor Imaging measures (DTI), on FTD subtypes. A total of 96 subjects with FTD and 84 healthy subjects (HS) were included in the study. A selection cohort was used to determine the set of features (measurements) and to use them to select the best machine learning classifier from a range of seven main models. The selected classifier was trained on a training cohort and tested on a third cohort (test cohort). The classifier was used to assess the classification power for binary (HS vs. FTD), and multiclass (HS and FTD subtypes) classification problems. In the binary classification, one of the new DTI features obtained the highest accuracy (85%) as a single feature, and when it was combined with other DTI features and two other common clinical measures (grey matter fraction and MMSE), obtained an accuracy of 88%. The new DTI features can distinguish between HS and FTD subgroups with an accuracy of 76%. These results suggest that DTI measures could support differential diagnosis in a clinical setting, potentially improve efficacy of new innovative drug treatments through effective patient selection, stratification and measurement of outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据